Payment overview · 2025
General Payments
$93.65
5 reported records · 3 companies
Healthcare provider profile · identity verified
Robert Harrison Hummer, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PORT CHARLOTTE, FL · NPI 1902886260
Verified facts
What the public records show
CMS Open Payments records show Robert Harrison Hummer, M.D. received $93.65 in general payments during 2025 across 5 reported records.
AstraZeneca Pharmaceuticals LP accounted for 63.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $58.98 | 63.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.91 | 19.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.76 | 17.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $93.65 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $58.98 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 298 | 138 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 286 | 118 |
| Lisinopril | Lisinopril | 256 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 251 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 213 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 77 |
| Losartan Potassium | Losartan Potassium | 175 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 61 |
| Metformin Hcl | Metformin Hcl | 138 | 59 |
| Gabapentin | Gabapentin | 136 | 67 |
| Omeprazole | Omeprazole | 121 | 56 |
| Tizanidine Hcl | Tizanidine Hcl | 109 | 62 |
| Alprazolam | Alprazolam | 96 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 36 |
| Famotidine | Famotidine | 87 | 43 |
| Simvastatin | Simvastatin | 81 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 34 |
| Ezetimibe | Ezetimibe | 76 | 30 |
| Glipizide Er | Glipizide | 75 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 33 |
| Buspirone Hcl | Buspirone Hcl | 67 | 31 |
| Montelukast Sodium | Montelukast Sodium | 65 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 33 |
| Methylprednisolone | Methylprednisolone | 62 | 45 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 50 |
| Meloxicam | Meloxicam | 59 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 24 |
| Eliquis | Apixaban | 56 | 23 |
| Metformin Hcl Er | Metformin Hcl | 56 | 26 |
| Tramadol Hcl | Tramadol Hcl | 56 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 27 |
| Mirtazapine | Mirtazapine | 54 | 27 |
| Spironolactone | Spironolactone | 54 | 28 |
| Trazodone Hcl | Trazodone Hcl | 54 | 26 |
| Alendronate Sodium | Alendronate Sodium | 51 | 25 |
| Farxiga | Dapagliflozin Propanediol | 49 | 18 |
| Furosemide | Furosemide | 49 | 26 |
| Carvedilol | Carvedilol | 46 | 25 |
| Finasteride | Finasteride | 46 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | suppressed |
| Atenolol | Atenolol | 43 | 19 |
| Donepezil Hcl | Donepezil Hcl | 43 | 18 |
| Celecoxib | Celecoxib | 42 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | 22 |
| Azithromycin | Azithromycin | 40 | 37 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Jardiance | Empagliflozin | 40 | 14 |
| Allopurinol | Allopurinol | 39 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 14 |
| Sertraline Hcl | Sertraline Hcl | 38 | 17 |
| Potassium Chloride | Potassium Chloride | 37 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | 13 |
| Bupropion Hcl | Bupropion Hcl | 32 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | 20 |
| Pregabalin | Pregabalin | 31 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | 13 |
| Glimepiride | Glimepiride | 28 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 13 |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | 11 |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | 13 |
| Folic Acid | Folic Acid | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | 11 |
| Estradiol | Estradiol | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 18 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Nystatin | Nystatin | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $93.65 · 5 records | AstraZeneca Pharmaceuticals LP | BREZTRI, JARDIANCE, OTEZLA, REPATHA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error